Today we announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage III/IV) following complete resection.

These data will be presented today at the 2026 American Society of Clinical Oncology (@ASCO) Annual Meeting (May 29-June 2) and published simultaneously in ASCO’s Journal of Clinical Oncology.

Read more: https://feeds.issuerdirect.com/news-release.html?newsid=8957702549517575&symbol=MRNA